Q-Line Biotech NSE SME IPO review

The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
As the company has no listed peers, it is trying to extract fancy price for its IPO.
Based on its overall financial data, the issue appears fully priced.
Well-informed investors may park moderate funds for long term.

About Company

Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges.

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBL’s key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipment’s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipment’s and devices as per the technical collaboration and specifications provided by the partners or companies.

With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share. The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes.

The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM group’s Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.

The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 – Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, company’s current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr.

IPO Lead Managers & Registrar

Financial Performance

On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.

For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.

If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained.

For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.

All amounts in Indian Rupees crores

Period Ended	Revenue	Expense	PAT	Assets
2023	₹184.81	₹154.97	₹32.10	₹251.58
2024	₹206.45	₹175.85	₹34.44	₹339.25
2025	₹322.58	₹261.43	₹28.13	₹455.49
Dec 2025	₹236.50	₹186.96	₹38.69	₹561.34

Dividend Policy

The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects.

Comparison with Listed Peers - for Fiscal 2025

As per the offer document, the company has no listed peers to compare with.

Name of the Company	Face Value (₹)	EPS basic (₹)	EPS Diluted (₹)	RONW (%)	P/E Ratio	NAV (₹)
Powerica Limited	5	15.26	15.26	15.37 %	24.45	99.76
Listed Peers
Cummins India Limited	2	72.15	72.15	26.45%	64.13	272.78
Kirloskar Oil Engines Limited	2	33.71	33.60	15.85%	43.24	212.60
NTPC Green Energy Limited	10	0.67	0.67	2.58%	129.40	21.88
Acme Solar Holdings Limited	2	4.55	4.53	5.59%	50.74	74.54
Adani Green Energy Limited	10	8.37	8.37	11.90%	101.53	76.62

Disclaimer: Above table shows earnings and P/E ratio as of 2025-26

Merchant Banker's Track Record

The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.

Conclusion - Apply for medium to long term

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion

Q-Line Biotech IPO FAQs

1. What is Q-Line Biotech IPO? ⌄

Q-Line Biotech IPO is SME IPO. The company is going to raise ₹214 Crores via IPO. The issue is priced at ₹326 to ₹343 per equity share. The IPO is to be listed on NSE SME.

2. When Q-Line Biotech IPO will open for subscription? ⌄

The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.

3. What is Q-Line Biotech IPO Investors Portion? ⌄

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

4. How to Apply the Q-Line Biotech IPO? ⌄

You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

5. What is Q-Line Biotech IPO Issue Size? ⌄

Q-Line Biotech IPO issue size is ₹214 crores.

6. What is Q-Line Biotech IPO Price Band? ⌄

Q-Line Biotech IPO Price Band is ₹326 to ₹343.

7. What is Q-Line Biotech IPO Lot Size? ⌄

The minimum bid is 800 Shares with ₹2,74,400 amount.

8. What is the Q-Line Biotech IPO Allotment Date? ⌄

Q-Line Biotech IPO allotment date is May 26,2026.

9. What is the Q-Line Biotech IPO Listing Date? ⌄

Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.

Concord Biotech IPO Date, Review, Price, Allotment Details

By Jagat Joshi
August 18, 2023

Concord Biotech IPO Details: Concord Biotech IPO date is fixed, the IPO is to hit the market on August 4 and will close on August 8, 2023. Concord Biotech IPO to raise around ₹1551 crores via IPO that comprises offer for sale up to 20,925,652 equity shares ₹10 each. The retail quota is 35%, QIB is 50%, and HNI is 15%.

Concord Biotech Limited is an R&D-driven biopharma Company based in Ahmedabad. They are one of the leading global developers and manufacturers of Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations. Concord Biotech has a global presence in more than 70 countries worldwide with efficient distribution infrastructure in markets like the USA, Europe, Japan, Latin America, Africa, and Asia, besides a significant presence in the Indian market. Concord is actively expanding its horizons by partnering with leading global pharmaceutical companies by meeting their product development needs for APIs & finished formulations.

They have six fermentation-based immunosuppressant APIs, including tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus. Their aim is to continue to grow their immunosuppressant API portfolio, which will remain one of the key contributors to the API business in the near future. In addition to our immunosuppressant API portfolio, they aim to increase APIs sales across other therapeutic areas, especially the (i) Anti-infective APIs. Our anti-infective APIs (ii) Oncology drug APIs. They offer six oncology drug APIs, including temsirolimus, everolimus, romidepsin, mitomycin, dactinomycin, and midostaurin.

As of March 31, 2022, they had 22 API products. They have three manufacturing facilities in the state of Gujarat, India. They have established two DSIR-approved R&D units with 163 members as of March 31, 2022. They have over 200 customers in over 70 countries as of March 31, 2022, for their APIs and formulations. They also entered into long-term supply agreements with some of our customers. Their API customers include Intas Pharmaceuticals Limited and Glenmark Pharmaceuticals Limited.

Objects of the Issue

Achieve the benefits of listing Equity Shares on the Stock Exchanges
Carry out the Offer for Sale of up to 20,925,652 Equity Shares by the Selling Shareholder.

Concord Biotech IPO Review (Apply or Not)

May Apply

Brokerage Firm IPO Review

Capital Market: To be updated soon
Religare Broking: To be updated soon
Hem Securities: To be updated soon
Arihant Capital: To be updated soon

Concord Biotech IPO Date & Price Band Details

IPO Open:	August 4, 2023
IPO Close:	August 8, 2023
IPO Size:	Approx ₹1551 Crores
Offer for Sale:	Approx 20,925,652 Equity Shares
Face Value:	₹1 Per Equity Share
IPO Price Band:	₹705 to ₹741 Per Share
IPO Listing on:	BSE & NSE
Retail Quota:	35%
QIB Quota:	50%
NII Quota:	15%
Discount:	N/A
DRHP Draft Prospectus:	Click Here
RHP Draft Prospectus:	Click Here
Anchor Investors List:	Click Here

Concord Biotech IPO Market Lot

The Concord Biotech IPO minimum market lot is 20 shares with ₹14,820 application amount. The retail investors can apply up-to 13 lots with 260 shares or ₹192,660 amount.

Application	Lot Size	Shares	Amount
Retail Minimum	1	20	₹14,820
Retail Maximum	13	260	₹192,660
S-HNI Minimum	14	280	₹207,480
B-HNI Minimum	68	1360	₹1,007,760

Concord Biotech IPO Allotment & Listing Dates

The Concord Biotech IPO date is August 4 and the close date is August 8. The Concord Biotech IPO allotment will be finalized on August 11 and the IPO listing on August 18.

Price Band Announcement:	July 31, 2023
Anchor Investors Allotment:	August 3, 2023
IPO Open Date:	August 4, 2023
IPO Close Date:	August 8, 2023
Basis of Allotment:	August 11, 2023
Refunds:	August 14, 2023
Credit to Demat Account:	August 17, 2023
IPO Listing Date:	August 18, 2023

You can check IPO subscription status and IPO allotment status on their respective pages.

Concord Biotech IPO Form

How to apply for the Concord Biotech IPO? You can apply for Concord Biotech IPO via ASBA available in your bank account. Just go to the online bank login and apply via your bank account by selecting the Concord Biotech IPO in the Invest section. The other option is you can apply for Concord Biotech IPO via IPO forms downloaded via NSE and BSE. Check out the Concord Biotech forms – Click BSE Forms & NSE Forms blank IPO forms download, fill, and submit in your bank or with your broker.

Concord Biotech Company Financial Report

₹ in Crores
Year	Revenue	Expense	PAT
2021	₹631	₹318	₹235
2022	₹736	₹495	₹175
2023	₹888	₹568	₹240

Concord Biotech IPO Valuation – FY2023

Check Concord Biotech IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.

Earning Per Share (EPS):	₹22.95 per Equity Share
Price/Earning P/E Ratio:	N/A
Return on Net Worth (RoNW):	20.06%
Net Asset Value (NAV):	₹123.31 per Equity Share

Peer Group

Divi’s Laboratories Limited
Suven Pharmaceuticals Limited
Laurus Labs Limited
Shilpa Medicare Limited

Company Promoters

SUDHIR VAID
ANKUR VAID

Concord Biotech IPO Registrar

Link Intime India Private Limited
Tel: +91 22 4918 6200
E-mail: concordbiotech.ipo@linkintime.co.in
Website: www.linkintime.co.in

Concord Biotech IPO Allotment Status Check

Check Concord Biotech IPO allotment status on Linkintime website allotment URL. Click Here

Concord Biotech IPO Lead Managers aka Merchant Bankers

Kotak Mahindra Capital Company Limited
Citigroup Global Markets India Private Limited
Jefferies India Private Limited

Company Address

Concord Biotech Limited
1482-86, Trasad Road, Dholka,
Ahmedabad – 382225, Gujarat, India
E-mail: complianceofficer@concordbiotech.com
Website: www.concordbiotech.com

Concord Biotech IPO FAQs

What is Concord Biotech IPO?

Concord Biotech IPO is a main-board IPO. They are going to raise ₹1551 Crores via IPO. The issue is priced at ₹705 to ₹741 pr equity share. The IPO is to be listed on BSE & NSE.

When Concord Biotech IPO will open?

The IPO is to open on August 4, 2023 for QIB, NII, and Retail Investors.

What is Concord Biotech IPO Investors Portion?

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

How to Apply the Concord Biotech IPO?

You can apply for Concord Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

How to Apply the Concord Biotech IPO through Zerodha?

Log in to Console in Zerodha Website or in Application. Go to Portfolio and Click on IPO. You will see the IPO Name “Concord Biotech”. Click on Bid Button. Enter your UPI ID, Quantity, and Price. Submit IPO Application Form. Now go to your UPI App on Net Banking or BHIM App to Approve the mandate. Open Demat Account with Zerodha.

How to Apply the Concord Biotech IPO through Upstox?

Log in to the Upstox Application with your credentials. Select the IPO. You will see the IPO Name “Concord Biotech”. Click on Bid Button. Confirm your Application. Now go to your UPI App on Net Banking or BHIM App to Approve the mandate. Open Demat Account with Upstox.

How to Apply the Concord Biotech IPO through Paytm Money?

Log in to Paytm Money Application with your credentials. Select the IPO. You will see the IPO Name “Concord Biotech”. Click on Bid Button. Confirm your Application. Now go to your UPI App on Net Banking or BHIM App to Approve the mandate. Open Demat Account with Paytm Money.

What is Concord Biotech IPO Size?

Concord Biotech IPO size is ₹1551 crores.

What is Concord Biotech IPO Price Band?

Concord Biotech IPO Price Band is ₹705 to ₹741.

What is Concord Biotech IPO Minimum and Maximum Lot Size?

The minimum bid is 20 Shares with ₹14,820 amount while the maximum bid is 260 shares with ₹192,660.

What is the Concord Biotech IPO Allotment Date?

Concord Biotech IPO allotment date is August 11, 2023.

What is the Concord Biotech IPO Listing Date?

Concord Biotech IPO listing date is August 18, 2023. The IPO is to list on BSE and NSE.

Note: The Concord Biotech IPO price band and date are officially announced. The IPO grey market premium (Concord Biotech IPO Premium) will be added to the IPO grey market page as it will start).

Follow IPO Watch for the Upcoming IPO news and their reviews, also keep following us on Twitter, Facebook, and Instagram. For our latest videos, subscribe to our YouTube channel.

Read Also:

Jagat Joshi

Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.